Fig. 4: Expanded outcomes of vaccination. | Nature Communications

Fig. 4: Expanded outcomes of vaccination.

From: Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine

Fig. 4

A Adjusted hazard ratios (aHRs) along with 95% confidence intervals, number needed to vaccinate (NNV), and predicted marginal rates per 1,000 people (in parenthesis) of experiencing events at 10d, 30d, 50d, 70d, and 90d post vaccination (last dose + 14d) for mRNA-1273 and BNT162b2, respectively. Time-to-event for (top-panel) infection, (middle-panel) serious adverse outcome of ICU admission/hospitalization/death/transfer-to-hospice, and (bottom-panel) adverse outcome of hospitalization/ICU admission/death/transfer-to-hospice whichever occurs first among all vaccinated individuals. B Number needed to vaccinate to observe a difference in infection rates between mRNA-1273 and BNT162b2 at 10d, 30d, 50d, 70d, and 90d post vaccination (last dose + 14d). Note that two models are considered for each outcome. (1) Unadjusted and with IPTW: weighted univariate model adjusting only for vaccine type. (2) Adjusted for imbalances: multivariable model adjusting for age, timing of vaccine, residence, prior history of Covid-19 diagnosis, and socioeconomic status.

Back to article page